This study will not use the services of study pe rsonnel where sanctions have been invoked or where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment). INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE Before study initiation, the investigator must ha ve written and dated approval/favorable opinion from the IRB/IEC for the protocol, consent form, participant recruitment materials (eg, advertisements), and any other written informati on to be provided to subjects/participants. The investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling information to be provided to subjects/participants and any updates. The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other information (eg, expedited safety reports, ame ndments, and administrative letters) according to regulatory requirements or institution procedures. Revised Protocol No.: 04 Date: 31-May-2019 166 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS The investigator should not implement any deviation or change to the protocol without prior review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if applicable, also by local health authority) except where necessary to eliminate an immediate hazard(s) to study subjects/participants. If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to obtaining relevant approval/favorable opinion(s) th e deviation or change will be submitted, as soon as possible to: •IRB/IEC for •Regulatory Authority(ies), if applicable by local regulations (per national requirements) Documentation of approval/favorable opinion signed by the chairperson or designee of the IRB(s)/IEC(s) and if applicable, also by local health authority must be sent to BMS. If an amendment substantially alters the study design or increases the potential risk to the participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects/participants currently enrolled in the study if they are affected by the amendment; and (3) the new form must be used to obtain consent from new subjects/participants prior to enrollment. If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s). FINANCIAL DISCLOSURE Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit comp lete and accurate financial certification or disclos ure statements to the appropriate h ealth aut horities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. INFORMED CONSENT PROCESS Investigators must ensure that subjects/participants are clearly and fully informed a bout the purpose, potential risks, and other critical issues regarding clinical studies in which they volunteer to participate. In situations where consent cannot be given to subjects/participants, their legally acceptable representatives (as per country guidelines) ar e clearly and fully informed about the purpose, potential risks, and other critical issues re garding clinical studies in which the participant volunteers to participate. Sponsor or designee will provide the investigator with an appropriate (ie, Global or Local) sample informed consent form which will include all elements required by ICH, GCP and applicable regulatory requirements. The sample informed cons ent form will adhere to the ethical principles that have their origin in the Declaration of Helsinki. Revised Protocol No.: 04 Date: 31-May-2019 167 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Investigators must: •Provide a copy of the consent form and written information about the study in the language in which the participant is most proficient prior to clinical study participation. The language must be non-technical and easily understood.